Background: Cardiac surgery involving cardiopulmonary bypass (CPB) is known to be associated with a transient postoperative immunosuppression. When severe and persistent, this immune dysfunction predisposes patients to infectious complications, which contributes to a prolonged stay in the intensive care unit (ICU), and even mortality. Effective prevention and treatment methods are still lacking. Recent studies revealed that acupuncture-related techniques, such as electroacupuncture and transcutaneous electrical acupoint stimulation (TEAS), are able to produce effective cardioprotection and immunomodulation in adult and pediatric patients undergoing cardiac surgery with CPB, which leads to enhanced recovery. However, whether perioperative application of TEAS, a noninvasive technique, is able to improve immunosuppression of the patients with post-cardiosurgical conditions is unknown. Thus, as a preliminary study, the main objective is to evaluate the effects of TEAS on the postoperative expression of monocytic human leukocyte antigen (-D related) (mHLA-DR), a standardized "global" biomarker of injury or sepsis-associated immunosuppression, in patients receiving on-pump coronary artery bypass grafting (CABG).
Background
Cardiac surgery involving cardiopulmonary bypass (CPB) is known to be associated with immune dysfunctions characterized by initial pro-inflammatory response and subsequent anti-inflammatory response [1] . If the following anti-inflammatory response is persistent and severe, it will lead to a long-lasting immunosuppressive state. This may result in an increased susceptibility to postoperative infectious complications, such as pneumonia or impaired wound healing, and thus a prolonged stay in the intensive care unit (ICU), or even mortality [2] [3] [4] [5] .
During CPB surgery, the exposure of blood to the non-physiological surfaces of the CPB apparatus [6] , cardiac arrest and ischemia/reperfusion injury of organs [7] , and translocation of endotoxins (lipopolysaccharide, LPS) across the ischemic gut wall [8] [9] [10] trigger a pronounced proinflammatory response, which is characterized by circulating cytokines, activation of endothelial cells and neutrophils, complement activation, circulating arachidonic acid metabolites, platelet-activating factors, and endothelins [11, 12] . As a physiologic countermeasure to ameliorate this harmful overactivation of innate immunity, a compensatory anti-inflammatory response often follows, which is known to cause a transient immunosuppression. It comprises secretion of anti-inflammatory cytokines such as interleukin (IL)-10 by monocytes and T cells, down-regulation of inflammatory cell surface receptors on neutrophils, impaired monocytic response to bacterial endotoxins [13, 14] , reduced production of interferon-γ (IFNγ), IL-2, and tumor necrosis factor (TNF)-α, as well as peripheral blood mononuclear cell (PBMC) proliferation in response to stimulation with phytohemagglutinin [15] . Generally, this immunosuppression is temporary and can be restored to normal. However, when serious and persistent, this immune imbalance is considered to contribute to postoperative infectious complications. Unfortunately, the counterbalancing long-lasting immunosuppressive responses still remain a clinical challenge.
Acupuncture is an ancient, non-drug treatment technology originating in China, which has been widely used worldwide. Recently, more and more studies have revealed that acupuncture is able to effectively regulate the function of the immune system, and this technique has been clinically regarded as a primary or adjuvant therapy measure for some immune-related diseases (e.g., asthma, allergic rhinitis, and rheumatic arthritis) [16] [17] [18] . In recent years, acupuncture-related techniques began to be applied to cardiac surgery for better recovery. Yang et al. [19] have shown that for adult patients undergoing heart valve replacements, electroacupuncture (EA) pretreatment can alleviate cardiac ischemia-reperfusion injury indicated by reduced overall serum troponin I release and dosage of inotropic drug use after surgery. Also, the ICU stay time can be shortened. Subsequently, pretreatment of transcutaneous electric acupoint stimulation (TEAS), a non-invasive acupoint stimulation technique, has produced similar cardioprotective effects in pediatric patients undergoing cardiac surgery. Moreover, alleviated inflammation indicated by reduced C-reactive protein (CRP) level in the early postoperative period was observed [20] .
Experimental studies also demonstrate that EA at the Zusanli (ST36) acupoint suppresses surgical trauma stress-induced lymphocyte apoptosis [21] and increases lymphocyte proliferation and IL-2 production in surgically traumatized rats [22] [23] [24] and IFNγ production of the spleen in mice [25] . Wang et al. further indicated that EA administration after surgical trauma increased Th1 cytokine protein and mRNA expression (IL-2 and IFNγ), and suppressed Th2 cytokine protein and mRNA expression (IL-4 and IL-10), involving the signaling pathways of ERK1/2, p38, NF-κB, and AP-1 in rats. These findings suggest that EA may improve immune suppression after surgical trauma [26] .
TEAS involves no risk of infection, needle-induced contagious disease, or fear of stimulation and is more "user friendly" with minimal training, which is more convenient for clinical application [27] . However, whether perioperative application of TEAS is able to improve postoperative immunosuppression of patients receiving onpump CABG is unknown.
In the current study, we will attempt to evaluate potential TEAS-induced reversal of CABG-associated immunosuppression. Previous clinical studies have shown that whether the patient is in a conscious state (i.e., preoperative or postoperative) or an anesthetic state, TEAS or EA applied to various surgical operations can produce beneficial effects, such as preventing hyperglycemia [28] , reducing intraoperative opioid consumption [29] , relieving post-hemorrhoidectomy-associated pain [30] , and improving immune and stress responses to surgery [31] . In order to maximize the possible benefit of TEAS, the perioperative administration (i.e., preoperative, intraoperative, and postoperative) of TEAS will be chosen in our trial.
Considering that this is a preliminary monocentric study, monocytic human leukocyte antigen (-D related) (mHLA-DR), a standardized "global" biomarker of injury-or sepsis-associated immunosuppression, serves as a primary endpoint, and other laboratory parameters (e.g., IL-6, IL-10) and clinical outcomes (e.g., postoperative infectious complications, ICU stay time, and mortality) as the secondary endpoints. Monocytic HLA-DR is a major histocompatibility complex (MHC) class II molecule and is predominantly expressed on monocytes/ macrophages [32] . Its surface expression is indispensable for antigen presentation [32] . Increased mHLA-DR expression reflects activation of immune cells, while diminished expression exhibits a phenotype with downregulation of antigen-presenting capacity and a shift from pro-to anti-inflammatory cytokine production [33, 34] . Moreover, surface expression of mHLA-DR is crucial for induction of adaptive immune responses [32, 35] . More importantly, accumulated clinical evidence has indicated that its persisting decreased expression is associated with adverse clinical outcomes (e.g., secondary infection risk, mortality) in patients with trauma [36] , burns [37] , pancreatitis, [38, 39] solid organ transplantation [40] , hepatic [41] or renal injury [42] , stroke [43] , myocardial infarction/heart failure and cardiac arrest [44] [45] [46] [47] , as well as sepsis [48] . The same is true of cardiac surgery with CPB. The quantification of mHLA-DR expression shows the best predictive power on outcome in pediatric and adult patients. Postoperative reduced mHLA-DR was associated with increased length of ICU stay/mechanical ventilation and development of postoperative sepsis [49, 50] .
In addition, some immune indicators, such as high mobility group box 1 protein (HMGB1) and regulatory T cells (Treg), possibly related to the mechanism of TEAS would also be measured. HMGB1, originally described as a DNA-binding protein and passively released by necrotic cells and actively released by macrophages/ monocytes, was discovered to be an essential cytokine that mediates the response to infection, injury, and inflammation [51] . Our previous animal study has shown that EA can inhibit excessive release of HMGB1 following myocardial ischemia and attenuate the associated inflammatory responses and myocardial injury during reperfusion [52] . Recently, HMGB1 was found to directly enhance the immune inhibitory functions of Treg and limit the number and activity of conventional T cells [53, 54] .
Treg cells are responsible for limiting tissue damage and inflammation associated with both innate and adaptive immune responses [55] . However, overactivation of Treg contributes to immunosuppression [56] . It was shown that the population of Treg in PBMCs was significantly increased at 48 h and 96 h after CABG with CPB [57] , which may contribute to CABG-associated immunosuppression. Thus, we speculate that the potential inhibition of excessive HMGB1 release of TEAS, consequently leading to attenuated function of Treg, may be associated with TEAS-induced reversal of immunosuppression, characterized by increased mHLA-DR.
Objective
The primary objective of the study is to evaluate the effects of perioperative TEAS on mHLA-DR expression in patients undergoing CABG with CPB.
Methods/design

Study design
This study is a preliminary, single-center, double-blind, randomized and controlled clinical trial (number of samples, n = 88) to explore the effects of TEAS therapy on improvement of postoperative immunosuppression indicated by diminished HLA-DR expression of patients receiving CABG (Fig. 1) . The trial will commence after ethical approval has been obtained from the Ethics Committee of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All studyrelated procedures will be performed only after subjects have given their written informed consent. The trial is designed following the Consolidated Standards of Reporting Trials (CONSORT) guidelines, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist (Additional file 1), and Standards for Reporting Interventions in Controlled Trials of Acupuncture (STRICTA) recommendations.
Participants
Current sample size justification
We calculated the sample size from the pilot study in our hospital based on the primary outcome: monocytic human leukocyte antigen DR (mHLA-DR). In that study, the expression of mHLA-DR 3 days after surgery was 36.17 ± 5.42% in the TEAS group and 27.33 ± 3.50% in the Sham TEAS group, with a power of 80% and a 5% type I error rate. Assuming that the dropout rate is 10%, 88 patients (n = 44 for each group) are needed.
Subject recruitment
Patients will be recruited from the Department of Thoracic and Cardiovascular Surgery, at Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Potentially eligible subjects who are scheduled for CABG under CPB for coronary disease will be invited to participate. Patients will be referred from a cardiothoracic surgeon, and then a research assistant will approach the subjects in the general ward pre operation. Patients will then be screened and consented for the study. Following the consent, eligible participants will be block randomized into two groups: (1) TEAS group (n = 44) and (2) Sham TEAS group (n = 44). All patients will receive standard operative procedure and postoperative analgesia management. The patients of the TEAS group will receive TEAS therapy in the perioperative period, and the Sham TEAS group will receive "pseudotherapy" performed without electrical stimulation in the perioperative period. Assessments will be conducted during the perioperative period until 30 days after surgery.
Inclusion criteria
The inclusion criteria are as follows: 
Exclusion criteria
The exclusion criteria are as follows: 
Randomization and blinding
A computer generates a random number sequence. The allocations will be printed and placed in separate sealed envelopes. The patients will be randomly divided into either the TEAS group or the Sham TEAS group in a 1:1 ratio. We set a blind code in case patients have adverse effects. The random code and blind code will be conducted using opaque envelopes by a "third party" independent of the study. The envelopes will be sealed and shuffled, and the assignment records will not be disclosed until the end of the study. Trial participants, cardiothoracic surgeons, anesthesiologists, outcome assessors, and data analysts will be blinded to the treatment allocation to minimize potential sources of bias. Only the nurse of the anesthesiology department (having received specialized acupuncture training) will know the participants' group allocations. However, this nurse will not know any other information about the patients.
Interventions
This trial will include two groups: the TEAS group and the group receiving transcutaneous acupoint pseudoelectric stimulation (Sham TEAS). In each group, there will be 44 patients receiving CABG with CPB. The patients of the TEAS group will receive TEAS therapy in the perioperative period, and in the Sham TEAS group, pseudotherapy without actual electrical stimulation will be performed in the perioperative period. The intervention details are as follows: 
Outcomes
Primary outcome measures
With mHLA-DR as the primary outcome of this clinical trial, the improvement of postoperative immunosuppression will be evaluated. Peripheral blood is collected from the patient to test this indicator at the following time points: one day before surgery, Day 1 after surgery (one day after surgery), Day 3 after surgery (3 days after surgery), and Day 5 after surgery (5 days after surgery).
The percentage of HLA-DR + /CD14 + cells in all CD14 + cells will be determined by flow cytometry (Becton-Dickinson, Franklin Lakes, NJ, USA) in the central lab of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine.
Secondary outcome measures
The secondary outcome measures are as follows: (1) Pneumonia: Pneumonia was defined according to the Centers of Disease Control and Prevention (CDC) guidelines [58] . Postoperative healthcare-associated pneumonia will be assessed throughout by radiograph suspicious for pneumonia, clinical signs and symptoms suspicious for pneumonia and positive culture from bronchoalveolar lavage, a positive blood 5 We will use Low-frequency electronic pulse therapeutic device G6805-2 (Huayi, Shanghai, China) for TEAS therapy, the frequency will be 2/100 Hz alternating and the intensity will be 15mA
culture not related to another infection, or a positive sputum culture. (2) Postoperative infection other than pneumonia: observe the incidence of incision infection and indwelling catheter infection after the surgery (fever, bacterial culture). We will record postoperative infectious complications according to the patient's medical history, imaging examination, clinical signs, and sputum culture within 30 days after the operation. 
Statistical analysis
All statistical analyses of the data will be performed using SPSS program V.21.0 (SPSS Inc., Chicago, IL, USA). A P value < 0.05 will be considered statistically significant. The intention-to-treat (ITT) approach will be used. Measured data will be expressed as mean ± SD ( − x± s) if it obeys a normal distribution or an approximate normal distribution. The median (interquartile range [IQR]) will be used if the data do not obey the normal distribution and count data will be expressed in terms of the number of cases.
To analyze the primary outcome, the expression of mHLA-DR (the percentage of HLA-DR+/CD14+ cells in all CD14+ cells) will be calculated by repeated measures analysis of variance (ANOVA), and the comparisons between the two groups will be made using the Student's t test. For the secondary outcomes, we will use chi-square tests for categorical data and repeated measures ANOVA or the Wilcoxon rank sum test for continuous data, according to whether the data are normally distributed. The variance analysis will be performed for the difference between the two groups and within a group. A stratified analysis will be performed to control the confounding factor if necessary. Data analysis will be conducted by statisticians who are independent of the research team.
Data collection and management
The data will be collected as primary and secondary outcome measures, with the above-described method. All data will be saved safely on an internal server of Shuguang Hospital, with complete confidentiality. The participants of this study will be cited with a code different from their real names. The data management program will be approved by the trial manager and other clinicians before the registration of the first participant.
Adverse events
The status related to adverse events is acquired according to the self-report of the patient or direct observation of clinicians or by non-induced query of the patient, and his/her clinical safety will be evaluated (see Table 1 ).
Quality control
The chief surgeon of the thoracic surgery department, the anesthetist to implement anesthetic management, the nurse of the anesthesiology department to carry out TEAS (having received specialized acupuncture training) as well as blood sampling personnel of clinical lab and data recording personnel are fixed to avoid bias from human operations. Specialized acupuncture training mainly includes selection of acupoints and the TEAS operation standard and procedure (see Table 2 ).
Discussion
Patients undergoing CABG with CPB are more prone to have immunosuppression, which may lead to postoperative infectious complications and a prolonged ICU stay, and even mortality. Previous studies have proved that acupuncture was able to improve patients' immune function. TEAS has a similar efficacy as electroacupuncture, but it is easier to operate, non-invasive, and easy to accept by patients. The current study aims to evaluate potential TEAS-induced reversal of decreased mHLA-DR (a standardized "global" biomarker of immunosuppression) and explore the possible underlying mechanism related to TEAS. Although the immediate clinical impact of this study is limited, its results will inform further research. Following demonstration of possible immunological efficiency, biomarker-guided immunological interventions of TEAS for immunosuppression should be performed in populations with sufficiently large sample size using relevant patient-centered clinical outcomes (e.g., mortality or infectious complications). Only in this way can we finally determine the clinical value of TEAS for counterbalancing CABG-associated immunosuppression and promote its application. Confirm the electric acupuncture apparatus is in power-up state, turn on the electric acupuncture apparatus, select corresponding parameters, and initiate TEAS therapy according to the patient's tolerance to electric stimulation 9 Maintenance treatment Maintain electric stimulation for 30 min, instruct the patient to protect the surgery area in acupuncture pin setting process, and closely examine the patient for adverse reactions of fainting, vomiting, and pain during acupuncture treatment; provide symptomatic treatment if needed 10 End of treatment Turn off the electric acupuncture apparatus, remove the electrode slices, and clear away connection wires. Check redness and swelling or other injury on the skin where electrode slice was attached, and provide symptomatic treatment if these symptoms occur responsible for the communication with all surgeons. WT is a local investigator in an involved center, and helped in the revision of the manuscript. YY participated in this study and is responsible for blood specimen collection, determination, and recording. LW participated in the study, is responsible for anesthetic management of the patients in the perioperative period, and contributed greatly to the successful implementation of the study. JGS and SW drafted the manuscript and contributed greatly to the study conception and design. All authors strictly reviewed and approved the final manuscript.
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